Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125283651 | 12528365 | 1 | I | 20160627 | 20160705 | 20160705 | EXP | FR-ASTRAZENECA-2016SE72446 | ASTRAZENECA | 52.00 | YR | M | Y | 0.00000 | 20160705 | MD | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125283651 | 12528365 | 1 | PS | IRESSA | GEFITINIB | 1 | Oral | U | 206995 | TABLET | |||||||||
| 125283651 | 12528365 | 2 | C | INNOHEP | TINZAPARIN SODIUM | 1 | 0 | ||||||||||||
| 125283651 | 12528365 | 3 | C | MORPHINIC | 2 | 0 | |||||||||||||
| 125283651 | 12528365 | 4 | C | ANALGESICS | UNSPECIFIED INGREDIENT | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125283651 | 12528365 | 1 | Non-small cell lung cancer metastatic |
| 125283651 | 12528365 | 4 | Pain |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125283651 | 12528365 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125283651 | 12528365 | Disease progression |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |